LPA and aortic valve calcification: These results provide a proof of concept that an orally delivered small-molecule inhibitor of Lp(a) might be a therapeutic option for patients with high levels of Lp(a) who are at risk of either atherosclerotic cardiovascular disease or calcific aortic valve disease.